20 news items
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
16 Jun 24
of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN
31 May 24
; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN
31 May 24
those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
REGN
31 May 24
and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health
2y72prhqraf1n p5f543g6n1tul5j1ugs968
REGN
31 May 24
programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third
ztx2p92r29zvbuyk
REGN
23 May 24
and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance
8regxs56vzmqooiobkyo79r8idwk0h yrcanypgn3
REGN
20 May 24
; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health
oksxvmfgkxu8c1q69g77igsdxxjalg10 6j
REGN
20 May 24
programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party
vq5 4halg
DV
JBL
REGN
19 May 24
were provided as reimbursements for credit card processing fees. As a result, the DOJ alleges that the average selling price of Regeneron's Eylea
md678r0ho8g04 ds24i88lkk8of58c
REGN
13 May 24
, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including
h5d ec19qg3
REGN
8 May 24
of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance
ax2mh53x78gn2ibckyqinj9sk4wbfx1hfawa403lag1x1p7dlok5te5tqk4
REGN
2 May 24
the billing and reimbursement processes for Medicare Part B treatments, allowing for efficient claims processing. Dupixent
w3w505ve5quegi0u02rz2v0i0sfl5f4
REGN
29 Apr 24
Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement
wjhg4wafiugh1wkfso1k7xd95semhmgeig4i8gwvp
REGN
22 Apr 24
and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from
jnytm 2jig
REGN
17 Apr 24
to drug distributors. These discounts were provided as reimbursements for credit card processing fees. As a result, the DOJ alleges that the average
prxn inrbqni
REGN
17 Apr 24
that the Company fraudulently inflated Medicare reimbursement rates for Eylea by knowingly submitting false average sales price reports to the Centers
rdk82fybituf1gfr rgthi1rzb3w4lf7vicimxx9rc8lfbq5xps44a
REGN
11 Apr 24
to drug distributors in the form of credit card fee reimbursements. According to the lawsuit, this created a higher average selling price for the Company's
ajzrxva9snz1dssepdk7sizcar30gk9p8fob5ea62oo58frg6p9
REGN
7 Apr 24
, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers
5ut94wgim7mxl qpfat3zpl56i5t9lylqfzdy4hdoub6sg9xrzlym7zr
REGN
25 Mar 24
, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including
- Prev
- 1
- Next